Scribd Logo
Upload

Welcome to Scribd!

  • 552 views

    HETERO LABS Project

    Uploaded by

    Anand Surya Ratnakumar
    Hetero Labs is a major Indian pharmaceutical company that produces both active pharmaceutical ingredients and finished drug formulations. It has over 22,000 employees and manufacturing facilities across the world. Hetero Labs is known for producing affordable generic versions of drugs and playing an important role in responding to public health crises like producing oseltamivir for H1N1 and remdesivir and favipiravir to treat COVID-19. The company has a strong global presence in over 126 countries and is one of the largest producers of antiretrovirals and active pharmaceutical ingredients worldwide.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    HETERO LABS Project

    Uploaded by

    Anand Surya Ratnakumar
    552 views30 pages
    Hetero Labs is a major Indian pharmaceutical company that produces both active pharmaceutical ingredients and finished drug formulations. It has over 22,000 employees and manufacturing facilities across the world. Hetero Labs is known for producing affordable generic versions of drugs and playing an important role in responding to public health crises like producing oseltamivir for H1N1 and remdesivir and favipiravir to treat COVID-19. The company has a strong global presence in over 126 countries and is one of the largest producers of antiretrovirals and active pharmaceutical ingredients worldwide.

    Original Title

    HETERO LABS project

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Hetero Labs is a major Indian pharmaceutical company that produces both active pharmaceutical ingredients and finished drug formulations. It has over 22,000 employees and manufacturing facilities across the world. Hetero Labs is known for producing affordable generic versions of drugs and playing an important role in responding to public health crises like producing oseltamivir for H1N1 and remdesivir and favipiravir to treat COVID-19. The company has a strong global presence in over 126 countries and is one of the largest producers of antiretrovirals and active pharmaceutical ingredients worldwide.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    552 views30 pages

    HETERO LABS Project

    Uploaded by

    Anand Surya Ratnakumar
    Hetero Labs is a major Indian pharmaceutical company that produces both active pharmaceutical ingredients and finished drug formulations. It has over 22,000 employees and manufacturing facilities across the world. Hetero Labs is known for producing affordable generic versions of drugs and playing an important role in responding to public health crises like producing oseltamivir for H1N1 and remdesivir and favipiravir to treat COVID-19. The company has a strong global presence in over 126 countries and is one of the largest producers of antiretrovirals and active pharmaceutical ingredients worldwide.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 30

    A

    STUDY ON
    "TRAINING AND DEVELOPMENT"
    With reference to
    "HETERO LABS LIMITED (UNIT-III) "
    NAKKAPALLI MANDAL, VISAKHAPATNAM.

    A project report submitted to


    The Department of Commerce and Management Studies,
    Adikavi nannaya University, Rajamahendravaram, in partial
    fulfilment of the requirements for the awards of the Degree
    of
    MASTER OF BUSINESS ADMINISTRATION

    Submitted by
    Bandharu Ratnakumar
    REGD.NO: 203103

    Under the Guidance of


    MR.K.S.V.N.SATYANARAYANA, MBA.
    PROFESSOR

    DEPARTMENT OF MANAGEMENT STUDIES


    D.N.R. SCHOOL OF BUSINESS MANAGEMENT
    (APPROVED BY AICTE, NEW DELHI and Affiliated
    to Adikavi Nannaya University, Rajamahendravaram)
    BALUSUMUDI, BHIMAVARAM
    WEST GODAVARI - 534202
    (2020 – 2022)
    1
    1.College CERTIFICATE

    2
    2.Completing Certificate

    3
    DECLARATION

    This is to certify that project report titled " TRANING


    AND DEVELOPMENT" with reference to HETERO
    LABS LIMITED (UNIT-III), VISAKHAPATNAM.
    Which is submitted by me in partial fulfilment of the
    requirement for the degree of Master of Business
    Administration to ADIKAVI NANNAYA UNIVERSITY,
    RAJAMAHENDRAVARAM comprises my original
    work and due acknowledgement has been made in
    text to all other text material used.

    I further declare that to the best of my knowledge


    and belief that the project report does not contain any
    part of any work which has been submitted for the
    award of any other degree/diploma/certificate in this
    University or any other universities.

    Place: Bhimavaram
    Date:

    (BANDHARU RATNAKUMAR)
    Regd.No: 203103
    4
    ACKNOWLEDGEMENT
    I sincerely acknowledge my grateful thanks to Sri. G. V. NARASIMHA
    RAJU Garu, President and Sri G. SATYANARAYANA RAJU Garu,
    Secretary & Correspondent, D.N.R. College Educational Institutions for
    providing me opportunity and lending his support to do the project work.

    My grateful thanks to Dr. D. VENKATAPATHI RAJU, Principal, D.N.R.


    School of Business Management for giving me an opportunity to do this
    project work.

    My sincere thanks goes to MUNTA DURGA SRINIVAS SR.


    MANAGER- HR OF HETERO LABS LIMITED (UNIT-III),
    VISAKHAPATNAM for giving permission to carry out this work and
    monitored my progress and arranged all facilities to make life easier.

    I am greatly indebted to, Dr.K. NARENDRA KUMAR Professor who


    inspire of being extraordinarily busy with his duties, took time out to hear, to
    guide and keep me on correct path.

    Finally, I thank my beloved PARENTS who helped me, encourage me and


    strengthened me for successful completion of the project. I also thank all
    my friends, relatives and all my well-wishers who have directly or
    indirectly contribute their help in the successful
    completion of my project work.

    I bow down to my all mighty.

    BHIMAVARAM.
    Date:
    (BANDHARU RATNAKUMAR)

    5
    INDEX

    CHAPTER TITLE PAGE NO.

    CHAPTER-I INTRODUCTION 1- 6
    IMPORTANCE OF THE STUDY
    NEED FOR THE STUDY
    OBJECTIVES OF THE STUDY
    SCOPE OF THE STUDY
    METHODOLOGY OF THE STUDY
    LIMITATIONS OF THE STUDY

    CHAPTER-II INDUSTRY PROFILE 7-13

    CHAPTER-III COMPANY PROFILE 14-21

    CHAPTER-IV QUESTIONNAIRE 22-40

    CHAPTER-V DATA ANALYSIS AND 41-63


    INTERPRETATION

    CHAPTER-VI FINDINGS, SUGGESTIONS AND 64-66


    CONCLUSION

    BIBLIOGRAPHY 67
    ANNEXURE 68-72

    6
    CHAPTER-1

    ➢ INTRODUCTION
    ➢ IMPORTANCE OF THE STUDY
    ➢ NEED FOR THE STUDY
    ➢ OBJECTIVES OF THE STUDY
    ➢ SCOPE OF THE STUDY
    ➢ METHODOLOGY OF THE STUDY
    ➢ LIMITATIONS OF THE STUDY

    7
    INTRODUCTION

    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    HETERO LABS

    Hetero is a globally renowned vertically integrated


    pharmaceutical player engaged in research and development,
    manufacturing, and marketing of high-quality chemical and
    biologic medicines across diverse therapeutic areas. Backed by
    27+ years of expertise in the pharmaceutical industry, Herero’s
    strategic business areas spread across APIs, Global Generics,
    Biosimilars and Custom Pharmaceutical Services. The
    company is among the largest producers of Active
    Pharmaceutical Ingredients (APIs) in the world.

    Hetero has 36 state-of-the-art manufacturing facilities


    strategically located worldwide, which has been approved by
    top pharma regulatory bodies of the world. Our portfolio
    includes 300+ products encompassing major therapeutic
    categories such as HIV/AIDS, Oncology, Cardiovascular,
    Neurology, Hepatitis, Nephrology etc. Hetero has a strong
    global presence in over 126 countries and focusses on making
    affordable medicines accessible to patients worldwide.

    Over the years, Hetero has established its strong leadership in


    ARVs and Antiviral therapies and caters to 40% of existing
    global demand for Anti-Retroviral (ARV) APIs and Finished
    Dosage Forms (FDFs) used in HIV/AIDS treatment.

    23
    A track record of responding to Global Public
    Health Emergencies

    The highlight of Herero’s 27+ years of existence has been its


    responsive actions to mitigate pandemics and life-threatening
    diseases afflicting communities across the world. By
    partnering with innovators for developing Oseltamivir to fight
    against Swine Flu Pandemic to enabling access to affordable
    Hepatitis C medicines in underdeveloped countries, Hetero has
    always endeavoured to do its bit at times of global health crises
    and save precious lives.

    Since the onset of the Covid-19 pandemic, Hetero has been


    proactive in responding to the various challenges surrounding
    it. It has been the first company to launch the licensed version
    of generic Remdesivir under the brand name ‘Covifor’ in India for
    treating severely infected patients and followed it up with
    Favipiravir (Favivir) to provide succour to those affected by mild
    and moderate symptoms. As of today, the company is among
    the largest manufacturers of Remdesivir globally.

    Illustrating its continuing commitment to play its part in the


    global fight against the pandemic, Hetero has entered into an
    agreement with the Russian Direct Investment Fund (RDIF) as a
    manufacturing partner for producing 100 million doses of the
    Sputnik V vaccine per year. This development also showcases

    24
    Hetero’s enduring spirit of collaboration and penchant for
    contributing to global health and well-being.

    Type Private
    Industry Pharmaceuticals
    Founded 1993
    Founder Dr BPS Reddy
    Headquarters Hyderabad India
    Key people Dr. Vamsi Reddy
    Number of employees Over 22,000

    Operations

    "Hetero group employs over 21,000 people. Hetero is a player in


    the active pharmaceutical ingredients market and finished
    dosages. It has marketing presence in over 127 countries.

    25
    Hetero has supplied antiretroviral drugs to patients across more
    than 100 countries globally.

    Today, Oseltamivir, sold under its brand name Fluvir, is also


    indicated for A[H1N1] virus, also known as swine flu. [citation
    needed]

    Hetero also produces hepatitis C antivirals such as Sofovir


    (sofosbuvir) and Ledifos (a fixed-dose combination of sofosbuvir
    and ledipasvir). [citation needed]

    Company structure

    Hetero Group's subsidiaries include Hetero Drugs, Hetero Labs,


    Hetero Research Foundation, Genx Laboratories and also foreign
    subsidiaries such as Camber Pharma Inc. in United States, Hetero
    Europe in Europe, and Richmond Labs in Argentina. The group is
    also investing in the wind power industry with a goal to reach
    26
    1000 megawatts by 2017.

    2009 Swine flu outbreak

    In 2009, as the swine flu outbreak was spreading across the globe
    and various health organizations and government agencies were
    piling up stocks of Oseltamivir as precautionary measures, Hetero
    supplied generic Oseltamivir under its brand name Fluvir.

    Hetero delivered 10 million doses of Oseltamivir to the Indian


    government in 2009, and shipped about 80 million doses to over
    60 countries. Hetero received its second order from Indian
    government to supply another 10 million doses of Oseltamivir
    later in 2009.

    COVID-19 experimental drugs

    The company has launched the generic version of experimental


    COVID-19 drug Remdesivir under brand name Covifor after
    acquiring license from Gilead Sciences and obtaining approval
    from CDSCO, the Indian drug control authority. On July 29, 2020
    the company launched its version of the anti viral drug Favipiravir
    under the brand name Favivir, after getting approval from Drugs
    27
    Controller General of India (DCGI), used in the treatment of mild
    to moderate COVID-19 patients. On November 27, 2020, Hetero
    Labs signed an agreement with the Russian Direct Investment
    Fund (RDIF) to manufacture 100 million doses of the Sputnik V
    vaccine.

    References

    "Archived copy". Archived from the original on 16 September


    2016. Retrieved 11 July 2016.CS1 maint: archived copy as title
    (link)

    ":: Welcome to Hetero ::". Heterodrugs.com. Archived from the


    original on 17 January 2014. Retrieved 11 January 2014.

    28
    "Hetero Wind power". Hetero. Retrieved 22 June 2018.

    Swine flu: Centre taps Hetero for generic Tamiflu supply Archived
    30 April 2009 at the Way back Machine

    Khomba Singh, ET Bureau 5 May 2009, 12.03am IST (5 May 2009).


    "Hetero bags mega chunk of govt's anti-flu drug deal - Economic
    Times". Economictimes.indiatimes.com. Retrieved 11 January
    2014.CS1 maint: multiple names: authors list (link)

    "Hyderabad pharma cos cash in on Swine-Flu fever".


    Moneycontrol.com. Retrieved 11 January 2014.

    Khomba Singh, ET Bureau 22 August 2009, 03.02am IST (22 August


    2009). "Hetero bags deal for 10 m Tamiflu - Economic Times".
    Economictimes.indiatimes.com. Retrieved 11 January 2014.CS1
    maint: multiple names: authors list (link)

    "Covid-19: Hyderabad-based Hetero Labs Ltd prices generic


    version of remdesivir at Rs 5,400 per vial". The Indian Express. 25
    June 2020.

    Kumar, N. Ravi (29 July 2020). "India's Hetero Labs wins approval
    to sell COVID-19 drug favipiravir". The Hindu. ISSN 0971-751X.
    Retrieved 9 September 2020.

    Das, Sohini (27 November 2020). "Hetero Labs to manufacture


    100 Mn doses of Sputnik V vaccine for India". Business Standard
    India. Retrieved 28 November 2020."

    29
    30

    You might also like